2008 PRESS RELEASES

ValiMed™ hospital client base doubles in FY08.

TUCSON, AZ and PARIS, France — November 6, 2008 — Following up on recent announcements related to global expansion, CDEX Inc. (OTCBB: CEXI) announces record ValiMed sales and more than doubling of its hospital client base in FY08, which ended October 31, with eleven ValiMed units sold or leased in the fourth quarter and, in addition, a backlog of orders. Going into FY09 with a backlog and a strong sales pipeline, CDEX projects that in the first six months of FY09 it will sell or lease over 25 new ValiMed units, continuing the trend of year-over-year growth.

The ValiMed Medication Safety and Narcotics Returns System improves patient safety by reducing medication errors, detecting harmful counterfeits, identifying narcotic diversion and training compounding medical personnel. Within seconds, ValiMed analyzes a medication’s spectroscopic signature and concentration and returns a quantitative result, requiring no user interpretation (see the Medication Safety section of our web site, www.cdexinc.com).

“We are pleased with the continuing penetration of ValiMed into the U.S. healthcare market and the expansion of that market globally,” said Malcolm Philips, CDEX CEO and Chairman. “We ended FY08 strong with an increase in the number of ValiMed units in the field, which not only increases sale and lease revenue, but also should contribute to a growing recurring revenue stream from service fees and the sale of supplies.”

“Momentum is building,” added Pascal Pouligny, VP and GM of the Medication Safety Division at CDEX. “Leading hospitals have adopted our technology and ValiMed has been cited by key national patient safety associations and organizations. This activity has resulted in an increasing number of requests for information and demonstrations of our system, translating into sales and leases. Indeed, we are benefiting from greater industry awareness about and critical acceptance of our Medication Safety Products.”

“Our future plans are exciting,” Pouligny continued. “First, we are introducing the next generation of ValiMed systems at the upcoming American Society of Health-System Pharmacists meeting in Orlando, Florida, in December. These new models and applications are flexible and designed to accommodate the varying requirements of our customers worldwide. Secondly, our strong U.S. sales pipeline should result in continued growth of our market share and branding of ValiMed as a standard of medication safety. Third, our international expansion should also continue in FY09 with the addition of new distributor geographies and opportunities related to co-development and marketing initiatives with key partners in Europe to customize our medication signatures offering for the ValiMed Systems. “

“In light of our progress, we believe more sales and leases of ValiMed systems will occur in the first two quarters of FY09 than occurred in all of FY08,” concluded Pouligny. (For more discussion listen to Mr. Pouligny’s briefing in the Investor Section of our website at www.cdexinc.com.)

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing chemical detection products in the medication safety and security markets. The Valimed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line is a revolutionary new tool in the global battle against abuse of illegal drugs such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets and applications. To meet its plans, however, CDEX must raise additional funds as set forth from time to time in its SEC filings. For more information, visit www.cdexinc.com or contact Dale Jahr, Director of Investor Relations, (djahr@cdex-inc.com) at (605) 399-3617.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

TUCSON, AZ — October 30, 2008 — CDEX Inc. (OTCBB: CEXI) announces that a subsidiary of BHP Billiton, the world’s largest mining company, donated a CDEX ID2 Meth Scanner™ to the Globe, Arizona Police Department for use in its battle against illegal drugs. The ID2 Meth Scanner™ is a hand-held, battery operated device that detects trace quantities of methamphetamine while scanning surfaces.

Francis McAllister, Finance Manager of the BHP Billiton Base Metals Group, which owns the Pinto Valley mine located near Globe, stated, “BHP Billiton is committed to the communities where we operate and we support their efforts to educate people about the harmful effects of drugs and to fight drug abuse. To this end, we donated a Meth Scanner to the Globe Police Department to assist in their efforts to fight drugs in our community. No community is immune to the dangerous grasp meth has taken and we will continue to support the community in the battle against this non-discriminating, devastating drug.”

Steve Schmidt, Vice-President of CDEX’s Security Division, thanked BHP Billiton for their leadership, activism and concern for the Miami-Globe community. “We are grateful for the exemplary participation of this community-minded company,” Schmidt said. “CDEX is honored to have its Meth Scanner selected as the tool to assist police in their fight against drug use and trafficking.

“CDEX pledges to work closely with Police Chief Lt. David Mullin, Sgt. James Durnan and local law enforcement to use the Meth Scanner to its maximum potential in the field,” Schmidt continued. “The devastating and growing impact of methamphetamines on our communities demands that we provide better weapons to law enforcement and Child Protective Service agencies to fight this war. We are inspired by the actions of BHP Billiton management and are pleased that CDEX can assist with their efforts to make this community a safer place to live and work.”

BHP Billiton, headquartered in Melbourne, Australia, is the world’s largest mining company and one of the world’s top producers of copper, silver, lead, uranium and zinc. BHP Billiton owns and operates the large Pinto Valley copper mine in the heart of Arizona’s Globe-Miami Mining District located about 90 miles east of metro Phoenix.

PHOTO OF METH SCANNER PRESENTATION TO GLOBE POLICE DEPARTMENT
From left: Police Chief David Mullin, Sgt. James Durnan, Francis McAllister, Finance Manager for the BHP Billiton Base Metals Group, and Tim Shriver, Jr., Sales Manager for CDEX’s Security Division.

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing chemical detection products in the medication safety and security markets. The Valimed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line is a revolutionary new tool in the global battle against abuse of illegal drugs such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets and applications. For more information, visit www.cdexinc.com or contact Dale Jahr, Director of Investor Relations, (djahr@cdex-inc.com) at (605) 431-7106.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Tucson, Arizona – October 23, 2008 – The Board of CDEX Inc. (OTCBB: CEXI) announces the appointment of Stephen A. McCommon as the company’s Chief Financial Officer, effective November 11, 2008. Mr. McCommon is a graduate of Arizona State University and has served as Accountant, Controller, CFO and VP of Finance with public/private companies during his career of over thirty years. He has most recently served in senior financial management at Applied Energetics, Inc. (NASDAQGM: AERG), also a Tucson, Arizona based public company. (Mr. McCommon’s bio can be reviewed on the CDEX web site at www.cdexinc.com.)

Mr. McCommon replaces August F. DeLuca who has led our financial team during the Company’s relocation of its professional services from Rockville, Maryland to Tucson, Arizona during 2007-2008. Mr. DeLuca will remain with the company as a consultant to provide continuity on financial matters.

“I am enthusiastic about joining CDEX, where my training and experience will assist the Company with its progress and growth,” said Mr. McCommon. “CDEX is a high technology company selling critically important products through its Medication Safety and Security Divisions on a worldwide basis, which fits well with my background and interests. The Company’s innovations address major problems facing the world today and I look forward to helping CDEX achieve its potential in the national and international arenas.”

“Stephen brings to CDEX a strong professional background and a wealth of experience with public companies. We are honored that he is joining the CDEX Team”, said Malcolm Philips, CDEX CEO and Chairman. “Stephen is a well qualified financial executive with extensive and ongoing hands-on experience in public company filings that will enable him to build upon Augie DeLuca’s work of structuring financial systems that support our growing businesses. I would like to thank Augie for his invaluable service in guiding the financial group during a critical transition of our professional services to Tucson, Arizona. We wish the very best for him and his wife Carolyn as they will now have more time to travel and pursue other interests.”

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing chemical detection products in the medication safety and security markets. The Valimed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line is a revolutionary new tool in the global battle against abuse of illegal drugs such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets and applications. For more information, visit www.cdexinc.com or contact Dale Jahr, Director of Investor Relations, (djahr@cdex-inc.com) at (605) 399-3617.

Any non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks such as those detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

CDEX Security Division introduces new, economical narcotics analyzer for in-station use – ID2 Narcolyzer™

Tucson, Arizona - October 14, 2008 - CDEX Inc. (OTCBB:CEXI) today announced the introduction of its latest product, the ID2 Narcolyzer™ at the COPSWEST Trade Show and Conference, recently held in Ontario, California. The ID2 Narcolyzer was featured at the CDEX display booth along with itssister product, the hand-held ID2 Meth Scanner™, showcasing CDEX’s breakthrough technology for the law enforcement market. The Narcolyzer is an economical, table-top device which employs the same technology used in the CDEX ValiMed CCT system, currently installed at hospitals around the world. The ID2 Narcolyzer identifies illegal drugs within seconds using CDEX’s patented enhanced photoemission spectroscopy. The unit will currently identify methamphetamine, cocaine, and heroin, and additional substances will be added based on market demand.

Steve Schmidt, VP of CDEX’s Security Division remarked, “The COPSWEST Show was a great success for CDEX. This prestigious conference featured over 300 exhibitors, a robust educational program and it attracted over 2,000 law enforcement officials eager to see the latest products and technology. We were the only exhibitor featuring illicit drug detection equipment and our booth was very busy from the opening until the closing bell. As we have seen at other demonstrations of our technology, there was fascination and interest for both of our featured products at the booth. The Meth Scanner provides a unique, reliable, and lightweight field instrument and the Narcolyzer is a fast, accurate, in-station device that can be purchased well below the price of conventional analytical equipment.”

Mr. Schmidt went on to say, “The overwhelmingly positive responses at COPSWEST validated the efficacy of our technology for law enforcement applications. The products performed flawlessly. Based on the success of its public debut, we will now proceed to a formal launch process for the Narcolyzer and continued market development for the Meth Scanner. The introduction of a second product will build brand awareness for CDEX’s ID2 family of illicit drug detectors and attract new distributors to drive increasing revenue streams going forward. We are very excited about our future as a supplier of unique products to help law enforcement in the battle against illegal drugs.”

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing chemical detection products in the medication safety and security markets The Valimed ™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2 ™ product line provides revolutionary new tools in the global battle against illegal drugs, such as methamphetamine. CDEX expects to advance its proprietary technology to serve additional markets and applications. Corporate headquarters and R&D facilities are located in Tucson, Arizona with an international office in Paris, France. For more information, visit www.cdexinc.com or contact Dale Jahr, Director of Investor Relations, (djahr@cdex-inc.com) at (605) 399-3617.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

ValiMed™ International expansion is moving forward on all planned fronts.

Tucson, Arizona – October 13, 2008 – CDEX Inc. (OTCBB: CEXI) announces that last week CEO Malcolm Philips and Pascal Pouligny, VP of its Medication Safety Division, met with European distributors to build upon the progress of its international expansion of ValiMed™. The CDEX delegation toured European hospitals in the United Kingdom, France and Spain, where interviews were held with hospital officials to discuss customized specifications for the Company’s medication safety products. Philips and Pouligny concluded that “our international expansion plans are moving forward on all fronts, with more details to follow in the coming weeks.” (For additional discussion see Mr. Philips’ CEO Corner on the Investor Page of the CDEX Web Site, www.cdexinc.com.)

Philips and Pouligny met with business partner GRIFOLS International SA (BMAD: GRF) and senior managers at the Vall D’Hebron Hospital in Barcelona, Spain. GRIFOLS, a global provider of healthcare products and services, is the exclusive distributor of Valimed in Spain, Portugal and Italy. “Valimed is an ideal extension of the products and services we offer,” said Xavier Guix, Marketing Director at Grifols. “We are pleased with our strong strategic association with CDEX, and look forward to expanding that relationship in the future.”

In France, following up on the recent introduction of Valimed at the Syndicat National des Pharmaciens Praticiens Hospitaliers et Praticiens Hospitaliers Universitaires Annual Meeting in Toulouse, Philips and Pouligny held discussions with Laurent Skvortzoff and Jean-Batiste Guillot, executives at EURAF, exclusive distributor of ValiMed in France. Together they met with senior management at major hospitals in Paris. Concluding the European tour, Philips met with senior management at the Charing Cross, Hammersmith and St. Mary’s hospitals in London.

“Our European tour strengthened existing business relationships while laying the foundations for new ones,” Philips remarked. “CDEX currently is represented by highly regarded distributors in European and Middle Eastern countries, with the objective of advancing an authoritative presence in all major markets in these regions. We are selling ValiMed units and supplies into the domestic US and international markets. With momentum increasing, we believe ValiMed will become the standard of care for medication safety that will accelerate our movement into markets around the world. We are continuing to expand our business alliances toward that goal.”

ValiMed™ improves patient safety by reducing medication errors, eliminating harmful counterfeits, identifying narcotic diversion and training compounding medical personnel. Within seconds Valimed analyzes a medication’s spectroscopic signature and concentration and returns a quantitative answer requiring no user interpretation.

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing chemical detection products in the medication safety and security markets. The Valimed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line is a revolutionary new tool in the global battle against abuse of illegal drugs such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets and applications. For more information, visit www.cdexinc.com or contact Dale Jahr, Director of Investor Relations, (djahr@cdex-inc.com) at (605) 399-3617.

Any non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks such as those detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Tucson, Arizona – October 6, 2008 – CDEX Inc. (OTCBB:CEXI) today announced a definitive agreement with ACE Trading Company Limited to be a distributor for the CDEX ID2 Meth ScannerTM . Ace Trading, based in Tokyo will distribute the Scanner to law enforcement, customs facilities, schools, home inspection and other markets throughout Japan where methamphetamine detection is critical.

Steve Schmidt, VP of CDEX’s Security Division noted “The use of methamphetamine has increased dramatically in Japan in recent years. There are an estimated 1-2 million users and Meth is the most widely used illegal drug in the country. The ID2 Meth ScannerTM is an important, new, front-line tool in the battle against methamphetamine manufacturing and use and the subsequent adverse public safety and health effects associated with passive exposure to the precursor chemicals and residual drug product.”

Mr. Schmidt went on to say, “We are very excited to have Ace Trading Company as part of our global distribution network. ACE is a major player in the Japanese marketplace, with extensive business relationships across the country. Mr. Goro Adachi, CEO of ACE Trading, was for many years an executive of one of the world’s largest trading companies. ACE works closely with many of the largest Japanese trading companies. CDEX’s strategy to develop a comprehensive global distribution network is being realized and establishing a significant presence in Japan is an important step forward. This increasing network of marketing representatives enables CDEX to expand sales going forward. We will continue to identify, qualify and sign distributors in the North American market and in selected international markets where methamphetamine abuse is taking a toll on human societies.”

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology. The company provides unique solutions to the challenges of identifying substances in difficult to monitor environments. CDEX technology is being adapted to market needs for medication validation, hazardous chemicals detection, and brand protection through analysis of counterfeit substances. CDEX is currently organized to serve two critical markets – Medication Safety and Security. The ValiMed System ™ is providing life-saving validation of high-risk medications as well as identifying narcotics diversion in healthcare facilities and pharmacies around the world. The ID2 Meth Scanner ™ is a revolutionary new tool in the global battle against the growing scourge of methamphetamine abuse and its toxic impact on the general public. Corporate headquarters and R&D facilities are located in Tucson, Arizona with international offices in Paris, France. For more information, visit www.cdexinc.com and www.valimed.com or contact Dale Jahr, Director of Investor Relations, (djahr@cdex-inc.com) at (605) 399-3617.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

TUCSON, AZ — September 25, 2008 — CDEX, Inc. (OTCBB: CEXI), a technology development Company providing applications in its patented Enhanced Photoemission Spectroscopy technologies, announced today the appointment of Dale T. Jahr as Director of Investor Relations, a newly created corporate position. Previously, Mr. Jahr held senior positions in investor and public relations, marketing, business development and strategic planning with both public and private companies, and served as an Economic Adviser to the United States Senate. (Mr. Jahr’s bio and an interview with him is published on the CDEX web site at www.cdexinc.com.)

“I am excited about joining the CDEX Team as it accelerates its transformation from research and development to full-scale innovation, manufacturing and commercial operations,” said Jahr. “CDEX is pushing the technology envelope in developing products that are impacting lives today and my job will be to keep the investing public informed and engaged in that journey.”

“Dale comes to us with an extensive background in all aspects of corporate communication, from investor and public relations to strategic planning,” said Malcolm Philips, CDEX CEO. “While he will contribute in a number of areas within the Company, he will give us a much needed and experienced focus on investor relations. With the ramp up of our two product lines and the projection for FY2009 to be another year of significant revenue growth, keeping the investing public aware of progress becomes strategically important. We are honored that Dale has joined the CDEX Team to lead that effort.”

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology. Currently CDEX is organized to serve two strategic markets – Medication Safety and Security. The Valimed™ System product line is providing life-saving validation of high-risk medications and return narcotics in healthcare facilities and pharmacies. The ID2 Meth Scanner™ product line is a revolutionary new tool in the global battle against the growing public safety threat of methamphetamine abuse and its toxic impact on the general public. Both of these product lines substantiate the superiority of our technology and also demonstrate the accuracy, reliability, speed and ease of use. CDEX expects to advance its proprietary technology to serve additional markets and applications. Corporate headquarters and R&D facilities are located in Tucson, Arizona with an international office in Paris, France. For more information, visit www.cdexinc.com and www.valimed.com or contact Steve Schmidt, VP Corporate Communications, (sschmidt@cdex-inc.com) at (520) 745-5172 x212.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

ValiMed™ received high interest from French University Hospital Pharmacists

Tucson, Arizona and Paris, France - September 23, 2008 – CDEX Inc. (OTCBB: CEXI) follows up on recent announcements related to international shipment of ValiMed™ Units and global expansion of the ValiMed™ client base, by announcing today that ValiMed™ was successfully introduced at the S.N.P.H.P.U. (Syndicat National des Pharmaciens Praticiens Hospitaliers et Praticiens Hospitaliers Universitaires) Annual Meeting in Toulouse, France, last week.

“We are very pleased with the launch of ValiMed™ at the S.N.P.H.P.U. Feedback from the show was unanimously positive and we are very excited going forward,” said Jean-Baptiste Guillot, Managing Director at EURAF. “France is engaged in a multi-year plan to secure the hospital medication process throughout the continuum of care (plan de sécurisation du circuit du medicament) through workflow and technology enhancements. ValiMed™ integrates well into this vision. At the show we demonstrated a new and valuable technology to hospital pharmacists and collected many leads for follow through in the coming weeks. Our next step is to establish a first-class pilot site in France for reference and publication purposes. I think we are off to a very good start,” added Guillot.

“It was important to introduce ValiMed™ to the University Hospital Pharmacists first. They represent the leading healthcare institutions in France and they have access to the latest and best technologies,” said Pascal Pouligny, Vice President and General Manager of the CDEX Medication Safety Division. “Our business partner in France, EURAF, did an outstanding job in organizing this event and introducing ValiMed to this market,” continued Pouligny.

The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures such as returned narcotics to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology. The company provides unique solutions to the challenges of identifying substances in difficult to monitor environments. CDEX technology is being adapted to market needs for medication validation, hazardous chemicals detection, and brand protection through analysis of counterfeit substances. CDEX is currently organized to serve two critical markets – Medication Safety and Security. The ValiMed System ™ is providing life-saving validation of high-risk medications as well as identifying narcotics diversion in healthcare facilities and pharmacies around the world. The ID2 Meth Scanner ™ is a revolutionary new tool in the global battle against the growing scourge of methamphetamine abuse and its toxic impact on the general public. Corporate headquarters and R&D facilities are located in Tucson, Arizona with international offices in Paris, France. For more information, visit www.cdexinc.com and www.valimed.com or contact Pascal Pouligny (ppouligny@cdex-inc.com) at (520) 745-5172.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Revenues to date surpass revenues for FY 2007; ID2 Meth Scanner™ ships; Global acceptance of ValiMed™ increases.

Tucson, Arizona – September 19, 2008 – With the filing of its 3Q FY08 Financial Report on Form 10-QSB, CDEX Inc. (OTCBB: CEXI) announced revenues for the first nine months of FY08 that surpassed revenues for the entire FY2007. Revenues for the third quarter of FY2008 reported on the Form 10-QSB did not reflect international shipments of the ValiMed™ Model CCT because of a delay in receiving the TUV approval which, as previously announced, was granted with resulting international shipments of the ValiMed Model CCT in the 4th quarter. Accordingly, while year to date revenues for FY2008 exceeded revenues for all of FY2007, the 3rd quarter revenues were lower than expected. (The Form 10 QSB is accessible at www.cdexinc.com.)

“The third quarter saw a number of milestone achievements in CDEX’s march to growth and profitability,” said Malcolm Philips, CDEX CEO and Chairman. “We have expanded our customer base for ValiMed in the United States and continued to grow the distribution channel internationally. Significantly, we have expanded our ValiMed Medication Signature Library to include heparin, which as widely reported has been involved in several recent tragic incidents. In addition, we sold and shipped the first units of our new product line, the ID2 Meth Scanner, and signed our first national and international Meth Scanner distributors. I should add that both the Meth Scanner and ValiMed product lines rely on the same patented technology, which gives the company leverage as we expand into new markets.” continued Mr. Philips. “With the launch of the Meth Scanner and the increasing market acceptance of ValiMed, we fully expect FY 2009 to be another year of record revenue, significantly surpassing FY 2008.” For more information on Mr. Philips’ assessment of the third quarter, visit the CEO Corner in the Investor Section of the CDEX Web Site (www.cdexinc.com).

The ValiMed Medication Validation System is used both to train compounding pharmtechs/nurses and to validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. The CDEX ID2 Meth Scanner is a hand held, battery operated device that detects low nanogram range quantities of methamphetamine in a continuous scan mode from standoff distances of around 2-8 inches. The Meth Scanner uses the same proven technology employed in ValiMed™ units around the world to give instantaneous results without disturbing the surfaces under investigation.

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology. With this technology, the company is providing unique solutions to the challenges of identifying substances in difficult to monitor environments. CDEX technology is being adapted to market needs for medication validation, hazardous chemicals detection, and brand protection through analysis of counterfeit substances. Currently, CDEX is organized to serve the two critical markets encompassing our existing product lines – Medication Safety and Security. The Valimed™ System product line is providing life-saving validation of high-risk medications and return narcotics in healthcare facilities and pharmacies. The ID2 Meth Scanner™ product line is a revolutionary new tool in the global battle against the growing scourge of methamphetamine a buse and its toxic impact on the general public. Corporate headquarters and R&D facilities are located in Tucson, Arizona with an international office in Paris, France. For more information, visit www.cdexinc.com and www.valimed.com or contact Steve Schmidt, VP Corporate Communications, (sschmidt@cdex-inc.com) at (520) 745-5172 x212.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Completion of certification testing provides avenues for expanded global markets for the new ValiMed™ Model CCT.

Tucson, Arizona – September 15, 2008 – Following recent announcements concerning reference testing of ValiMed™ Units at international flagship hospitals, CDEX Inc. (OTCBB: CEXI) announces that its new ValiMed Model CCT has successful completed certification testing and TUV Rheinland of North American Inc. (www.us.tuv.com) has authorized use of the TUV mark. The testing and evaluations were conducted in conjunction with Elliot Laboratories (www.elliotlabs.com) for compliance with Electromagnetic Testing for Electrical Equipment for Measurement, Control and Laboratory Use.

The new ValiMed™ Medication Validation and Narcotics Return System (Model CCT), introduced first to the international market, is a light-weight, compact, table top instrument that can be used in virtually any clinical environment where high-risk IV medications are compounded before being dispensed to the patient or where narcotics are returned after being used.

“The award of the TUV mark reflects completion of exhaustive testing of the new ValiMed Model and dedication of the CDEX Team that developed it,” said Carlos Alvarez, VP of CDEX’s Technical Operations Division. “The evaluation and testing was conducted to the same requirements and standards utilized by UL for the U.S. market, ULC for the Canadian market, CE for the European Union market, and CB Scheme for other international markets. In addition, in our design of the CCT Model we assured that it only contained RoHS compliant components, a step forward for the international marketplace.”

“The award of the TUV mark is another major milestone in the manufacturing and marketing of the CCT,” said Tim Shriver, CDEX COO. “This step was crucial in expanding our distributor base to other countries and providing a global product that will improve medication safety throughout the world.”

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology. The company provides unique solutions to the challenges of identifying substances in difficult to monitor environments. CDEX technology is being adapted to market needs for medication validation, hazardous chemicals detection, and brand protection through analysis of counterfeit substances. CDEX is currently organized to serve two critical markets – Medication Safety and Security. The ValiMed System ™ is providing life-saving validation of high-risk medications as well as identifying narcotics diversion in healthcare facilities and pharmacies around the world. The ID2 Meth Scanner ™ is a revolutionary new tool in the global battle against the growing scourge of methamphetamine abuse and its toxic impact on the general public. Corporate headquarters and R&D facilities are located in Tucson, Arizona with international offices in Paris, France. For more information, visit www.cdexinc.com and www.valimed.com or contact Pascal Pouligny (ppouligny@cdex-inc.com) at (520) 745-5172.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

New CDEX Web Site contains updated information concerning the company and its ValiMed™ and ID2 Meth Scanner product lines for clients, shareholders and distribution partners.

Tucson, AZ (Business Wire) – Sept. 10, 2008 – CDEX Inc. (OTC BB: CEXI) announces the launch of its redesigned and updated corporate web site, www.CDEXInc.com. The new site provides customers, investors and the general public a comprehensive source for important information about the company, its products and its mission. It features in-depth presentations of the history, technology and people that make CDEX a fast-growing and exciting global technology development company. It provides extensive insight into the company’s two product lines, ValiMed™ (validating high risk medications and narcotics for the health care markets) and the ID2 Meth Scanner™ (detecting trace quantities of methamphetamine on virtually all surfaces in a scan mode). The site features Resource Centers with many useful downloads and links and contains a robust Investor Information section to keep existing and potential investors informed and up-to-date. Customers may also purchase products using the Shopping Cart function.

“Redesign and deployment of the new web site was truly a dynamic team effort,” said Steve Schmidt, CDEX VP and GM of the Security Division who led the Web Site Redesign Project. “We assembled a great creative team of Karen Scott, owner of Gr8Scott Design, Ildiko Palyka, owner of Ildiko Designs, and Robin Mangan, copy writer. We then involved the entire CDEX team in the project.” He went on to say, “In many ways, corporate web sites are the face of business in today’s global economy. We are very pleased to now have a web site where form and function combines to more fully portray the dynamic nature of our technology, our company capabilities and our mission of providing innovative solutions in an unsafe world. We look forward to the daily challenge to improve and update the site and welcome feedback from our visitors.”

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology. With this technology, the company is providing unique solutions to the challenges of identifying substances in difficult to monitor environments. CDEX technology is being adapted to market needs for medication validation, hazardous chemicals detection, and brand protection through analysis of counterfeit substances. Currently, CDEX is organized to serve the two critical markets encompassing our existing product lines – Medication Safety and Security. The Valimed™ System product line is providing life-saving validation of high-risk medications and return narcotics in healthcare facilities and pharmacies. The ID2 Meth Scanner™ product line is a revolutionary new tool in the global battle against the growing scourge of methamphetamine a buse and its toxic impact on the general public. Corporate headquarters and R&D facilities are located in Tucson, Arizona with an international office in Paris, France. For more information, visit www.cdexinc.com and www.valimed.com or contact Steve Schmidt, VP Corporate Communications, (sschmidt@cdex-inc.com) at (520) 745-5172 x212.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Nursing Journal Discusses Benefits of CDEX’s ValiMed™ Technology in the Monitoring of Narcotic Returns in the Operating Suite

Tucson, Arizona - September 9, 2008 – CDEX Inc. (OTCBB: CEXI). CDEX Inc. (OTCBB: CEXI). An article published in the August issue of the Association of Perioperative Registered Nurses (AORN) Journal documents the benefits of CDEX ‘s Enhanced Photoemission Spectroscopy Technology in reducing narcotics diversion in the healthcare community. AORN J 88 (August 2008) 249–252. © AORN, Inc, 2008. http://www.aornjournal.org/article/S0001-2092(08)00258-5/abstract. The AORN Journal publication conclusion is similar to an earlier American Journal of Health-System Pharmacists peer reviewed article detailing an 18 month independent study of the ValiMed™ Medication Validation System. Am J Health-Syst Pharm--Vol 65, pp 49-54, Jan 1, 2008.

“Drug diversion is an ongoing problem in health care settings,” said Dr. Kevin B. Sharer, MD, MBA, CPE and author of the publication. “Records of the flow of controlled substances are kept by various accounting systems, but these systems can be inaccurate because the returned medications rarely are tested to verify that they have not been diluted or replaced. For example, fentanyl is a potent narcotic that is administered frequently in hospitals for the relief of pain as an adjunct to anesthesia in surgical procedures. It is diverted primarily from operating rooms through product substitution or outright theft, resulting in the potential under dosing of patients and falsifying of records,” continued Dr. Sharer. “The ValiMed System technology provides a quick and relatively inexpensive solution to this problem.”

The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures such as returned narcotics to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology. With this technology, the company is providing unique solutions to the challenges of identifying substances in difficult to monitor environments. CDEX technology is being adapted to market needs for medication validation, hazardous chemicals detection, and brand protection through analysis of counterfeit substances. Currently, CDEX is organized to serve the two critical markets encompassing our existing product lines – Medication Safety and Security. The Valimed™ System product line is providing life-saving validation of high-risk medications and return narcotics in healthcare facilities and pharmacies. The ID2 Meth Scanner™ product line is a revolutionary new tool in the global battle against the growing scourge of methamphetamine a buse and its toxic impact on the general public. Corporate headquarters and R&D facilities are located in Tucson, Arizona with an international office in Paris, France. For more information, visit www.cdexinc.com and www.valimed.com or contact Steve Schmidt, VP Corporate Communications, (sschmidt@cdex-inc.com) at (520) 745-5172 x212.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Tucson, Arizona - September 3, 2008 – CDEX Inc. (OTCBB: CEXI) follows up on recent announcements related to international shipment of ValiMed™ Units and global expansion of the ValiMed client base, by announcing today new additions to its US sales force. In response to a growing ValiMed client base, CDEX has appointed Greg Firmbach as Sales Manager of its newly created Eastern Territory and signed ABMI CORP (All Business Machines, Inc – Sacramento, CA - (http://abmicorp.com/) as an authorized Distributor of ValiMed focusing on VA Hospitals and other Federal Government Healthcare Facilities.

“I am pleased to announce that Greg has agreed to head the Medication Safety Division’s sales force for the Eastern Territory. Greg is an accomplished and passionate sales professional with an impressive track record of selling new technologies and services to the Healthcare Industry. He is a great addition to our Team,” said Pascal Pouligny, VP and GM of the Medication Safety Division. “ABMI Corporation is a Service-Disabled Veteran-Owned Small Business and an SBA certified HUB-Zone Corporation that has partnered with Fortune 500 Companies to manage their procurement contract processes related to Public Policy Goal Attainment acquisitions. ABMI has a proven record of providing the highest quality products, with proven customer satisfaction. This translates into a very strong reputation among Veteran Administration Hospitals and Federal Agencies. We are honored by their addition to our channel strategy in the US.”

“The timing of our sales force expansion is perfect. Awareness of ValiMed technology has increased dramatically over the last months and we receive daily contacts from hospitals around the world inquiring about VAliMed or requesting in-house presentations to their pharmacy and medication safety staffs,” continued Mr. Pouligny. “The ValiMed System is a complete solution for training, testing and control of compounded IV medications. We are committed to helping our customers integrate ValiMed into their process flow in order to maximize the clinical and financial return on their investment.”

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology. With this technology, the company is providing unique solutions to the challenges of identifying substances in difficult to monitor environments. CDEX technology is being adapted to market needs for medication validation, hazardous chemicals detection, and brand protection through analysis of counterfeit substances. Currently, CDEX is organized to serve the two critical markets encompassing our existing product lines – Medication Safety and Security. The Valimed™ System product line is providing life-saving validation of high-risk medications and return narcotics in healthcare facilities and pharmacies. The ID2 Meth Scanner™ product line is a revolutionary new tool in the global battle against the growing scourge of methamphetamine a buse and its toxic impact on the general public. Corporate headquarters and R&D facilities are located in Tucson, Arizona with an international office in Paris, France. For more information, visit www.cdexinc.com and www.valimed.com or contact Steve Schmidt, VP Corporate Communications, (sschmidt@cdex-inc.com) at (520) 745-5172 x212.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

A very important milestone in the CDEX International Development Plan is reached today with the first international shipments of the new ValiMed™ Model CCT System.

Tucson, Arizona - August 21, 2008 – Following recent announcements of the reference testing of ValiMed™ Units at four flagship hospitals in Europe and the Middle East, CDEX Inc. (OTCBB: CEXI) announces today the first shipments of the new ValiMed™ Model CCT System to international customers.

The new ValiMed™ Medication Validation and Narcotics Return System (Model CCT), introduced first to the international market, is a light-weight, compact table top instrument that can be used in virtually any clinical environment where high-risk IV medications are compounded before being dispensed to the patient or where narcotics are returned after being used.

“From the inception of the CCT through its final design we have integrated new and innovative specifications to address market needs on a global basis” said Tim Shriver, CDEX Inc, COO. “Our engineering team worked hard in developing this revolutionary device that encompasses all the proven features of the current ValiMed™ VM Model as well as adding new reporting capabilities and software enhancements to further increase the operating value of the system”.

“The vision has become a reality. We have received very positive feedback from our validation sites and have incorporated input from our international customers and partners in the final design of the CCT.  The new ValiMed™ Model CCT will be displayed at major Pharmacy Conferences in France, Spain and Italy this fall and we are very excited about going forward” said Pascal Pouligny, VP and GM of the Medication Safety Division.  “The shipment of CCTs to international customers marks another major milestone in our International Development Plans.”

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology. With this technology, the company is providing unique solutions to the challenges of identifying substances in difficult to monitor environments. CDEX technology is being adapted to market needs for medication validation, hazardous chemicals detection, and brand protection through analysis of counterfeit substances. Currently, CDEX is organized to serve the two critical markets encompassing our existing product lines – Medication Safety and Security. The Valimed™ System product line is providing life-saving validation of high-risk medications and return narcotics in healthcare facilities and pharmacies. The ID2 Meth Scanner™ product line is a revolutionary new tool in the global battle against the growing scourge of methamphetamine abuse and its toxic impact on the general public. Corporate headquarters and R&D facilities are located in Tucson, Arizona with an international office in Paris, France. For more information, visit www.cdexinc.com and www.valimed.com, or contact Steve Schmidt, VP Corporate Communications, (sschmidt@cdex-inc.com) at (520) 745-5172 x212.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Tucson, Arizona – Malcolm Philips, Chief Executive Officer of CDEX, Inc. (OTCBB: CEXI) (www.cdex-inc.com) updated the investment community in an all-new interview with www.wallst.net. Topics covered in the interview include an overview of the company and its growth strategy, recent press releases, market opportunity, and upcoming milestones for investors to watch for.

To hear the interview in its entirety, visit http://www.wallst.net, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window.

About WallSt.net

www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. (http://www.financialmediagroupinc.com). The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net, a financial social network for investors, and Financial Filings Corp. (http://www.financialfilings.com), a provider of media and compliance solutions to publicly traded companies. In addition to WallSt.net, WallStreet Direct, Inc. owns and operates WallStRadio (http://www.wallstradio.com), a business and finance podcast Web site. Financial Filings Corp. is expecting to receive two hundred eighty dollars from CDEX, Inc. for the dissemination of this press release. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp.

Contact: www.WallSt.net

800-4-WALLST

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology. With this technology, the company is providing unique solutions to the challenges of identifying substances in difficult to monitor environments. CDEX technology is being adapted to market needs for medication validation, hazardous chemicals detection, and brand protection through analysis of counterfeit substances. Currently, CDEX is organized to serve the two critical markets encompassing our existing product lines – Medication Safety and Security. The Valimed™ System product line is providing life-saving validation of high-risk medications and return narcotics in healthcare facilities and pharmacies. The ID2 Meth Scanner™ product line is a revolutionary new tool in the global battle against the growing scourge of methamphetamine abuse and its toxic impact on the general public. Corporate headquarters and R&D facilities are located in Tucson, Arizona with an international office in Paris, France. For more information, visit www.cdexinc.com and www.valimed.com, or contact Steve Schmidt, VP Corporate Communications, (sschmidt@cdex-inc.com) at (520) 745-5172 x212.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Monday July 21, 2008, 7 a.m. EST NEW YORK and TUCSON, ARIZONA, /PRNewswire-FirstCall/ — CDEX Inc. (OTCBB: CEXI), a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology, today announced that Malcolm Philips, the company's President and CEO, is featured in an exclusive interview on WallSt.net's 3-Minute Press Show to discuss recent press releases related to its two product lines, ValiMed™ and the ID2 Meth Scanner ™. To view the clip in its entirety, visit: http://tv.wallst.net/3-minute-press/167/741/CEXI/malcolm-philips/cdex-inc.

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology. With this technology, the company is providing unique solutions to the challenges of identifying substances in difficult to monitor environments. CDEX technology is being adapted to market needs for medication validation, hazardous chemicals detection, and brand protection through analysis of counterfeit substances. Currently, CDEX is organized to serve the two critical markets encompassing our existing product lines – Medication Safety and Security. The Valimed™ System product line is providing life-saving validation of high-risk medications and return narcotics in healthcare facilities and pharmacies. The ID2 Meth Scanner™ product line is a revolutionary new tool in the global battle against the growing scourge of methamphetamine a buse and its toxic impact on the general public. Corporate headquarters and R&D facilities are located in Tucson, Arizona with an international office in Paris, France. For more information, visit www.cdexinc.com and www.valimed.com or contact Steve Schmidt, VP Corporate Communications, (sschmidt@cdex-inc.com) at (520) 745-5172 x212.

About WallStreet Direct, Inc.

WallStreet Direct, Inc. operates WallSt.net (http://www.wallst.net), a leading source of up-to-the-minute business news, comprehensive financial tools and original multimedia content for the investment community. In addition to WallSt.net, WallStreet Direct owns and operates WallStRadio (http://radio.wallst.net), an online hub for business podcasts from well-known business news personalities and publishers, and WallStTV (http://tv.wallst.net), a hub for business and finance video content. We have received two hundred eighty dollars from CDEX Inc. for the dissemination of this press release. To read our full disclaimer, and for a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.php.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

CDEX sells and delivers ID2 Meth Scanners™ for methamphetamine detection to U.S. clients in the Law Enforcement and Home Inspection Markets, and to U.S. and international distributors

TUCSON, AZ — (MARKET WIRE) — July 17, 2008 — CDEX Inc. (OTC BB:CEXI) announces its first sales and deliveries of ID2 Meth Scanners™ for methamphetamine detection to U.S. clients in the Law Enforcement and Home Inspection Markets, and to U.S. and international distributors. The ID2 Meth Scanner™ is a hand-held, battery operated device that detects trace amounts of methamphetamine (low nanogram range) on virtually any surface while in the continuous scan mode. It employs the same CDEX patented Enhanced Photoemission Spectroscopy technology used in the ValiMed™ System, currently saving lives in hospitals today. "We are excited about the commercialization of the ID2 Meth Scanner following two years of extensive R&D, beta testing and market research by the CDEX Team,” said Steve Schmidt, VP and General Manager of CDEX’s Security Division. The scourge of methamphetamine abuse is growing exponentially around the world. It is estimated that over 13 million are addicted to methamphetamine in the U.S. alone, raising significant concerns of officials in law enforcement, homeland security, school systems and the border patrol, as well as the unsuspecting consumers purchasing homes and used automobiles. “Residue from use or production of methamphetamine in homes, schools, automobiles, hotels and public buildings raises serious health risks for those exposed,” Schmidt continued. “CDEX plans to build an extensive distribution network around the world, particularly in countries where meth abuse, manufacturing or distribution is at dangerous levels. This marks the first step in that process.”

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology. With this technology, the company is providing unique solutions to the challenges of identifying substances in difficult to monitor environments. CDEX technology is being adapted to market needs for medication validation, hazardous chemicals detection, and brand protection through analysis of counterfeit substances. Currently, CDEX is organized to serve the two critical markets encompassing our existing product lines – Medication Safety and Security. The Valimed™ System product line is providing life-saving validation of high-risk medications and return narcotics in healthcare facilities and pharmacies. The ID2 Meth Scanner™ product line is a revolutionary new tool in the global battle against the growing scourge of methamphetamine abuse and its toxic impact on the general public. Corporate headquarters and R&D facilities are located in Tucson, Arizona with an international office in Paris, France. For more information, visit www.cdexinc.com and www.valimed.com, or contact Steve Schmidt, VP Corporate Communications, (sschmidt@cdex-inc.com) at (520) 745-5172 x212.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

CDEX Inc and EURAF enter into distribution agreement for the ValiMed™ Medication Validation System in France.

TUCSON, Arizona and Paris, France – July 14, 2008 – CDEX Inc. (OTCBB: CEXI) follows up on recent announcements regarding continued international expansion by announcing today a business partnership agreement with EURAF to distribute ValiMed™ in France. The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety and a reduction in medication errors. ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation. “At EURAF our focus is to provide hospital pharmacies with state-of-the-art technologies to improve workflow and enhance patient medication safety”, said Laurent Skvortzoff and Jean-Baptiste Guillot, business associates and managers at EURAF. “ValiMed provides valuable synergies with our pharmacy automation solutions and addresses the critical issue of reliable and safe compounding of IV medication. We are very excited about this new relationship with CDEX.” “France is continuously ranked as one of the leading countries in the world for its healthcare services and the standards and quality of care”, said Malcolm Philips, CDEX President and CEO. “We are very pleased that EURAF is joining the CDEX family. We look forward to developing a long and lasting relationship and working together to become a major player in the patient medication safety arena in France.”

About CDEX Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market. For more information, visit www.cdex-inc.com and www.valimed.com or contact Steve Schmidt (sschmidt@cdex-inc.com) or Pascal Pouligny (ppouligny@cdex-inc.com) at 520.745.5172.

About EURAF

EURAF is a distribution company dedicated to the marketing and servicing of foreign industrial products on the French territory, on an exclusive basis. With a long experience in pharmaceutical processing, packaging and control equipment, EURAF is focusing on two markets with large potential: (a) on line quality control equipment for packaging machinery and (b) equipment for the improvement of the quality of medication delivery in hospital and clinic pharmacies, a market driven by the French government’s plan for improvement of security and traceability in the healthcare system. EURAF is one of the leading suppliers in France, with a significant portfolio of complementary products. More information about EURAF can be found at http://www.euraf.fr/

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Recording of the teleconference will be placed on the CDEX web site at www.cdexinc.com.

TUCSON, AZ--(MARKET WIRE)—July 8, 2008 -- CDEX Inc. (OTCBB: CEXI) announces that on July 8, 2008 it held a call-in teleconference to update investors and field questions regarding performance and the recent financing agreement. Malcolm Philips (CEO), Tim Shriver (COO) and Steve Schmidt (VP and GM, Security Division) provided the briefing and responded to questions. Click here to listen to the recording of the teleconference.

About CDEX Inc. CDEX, a technology development company currently developing and marketing products using its patented/patent pending chemical detection technologies, is focused on (i) identification of substances of concern (e.g., explosives and illegal drugs, for security markets); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of compounded medication and detection of counterfeit or sub-par products, for the medical and brand protection markets). ValiMed™ and the ID2 Meth Scanner™ are CDEX solutions for the medication safety and security markets. Corporate headquarters and R&D facilities are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Steve Schmidt (sschmidt@cdex-inc.com) at 520.745.5172.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the Protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

As Demand for Products Increases, New Funding Enables CDEX to Expand  its Product Portfolio and Distribution into Global Markets; Investor Call In Teleconference scheduled for July 8, 2008 to discuss Financing Package

Tucson, Arizona –(MARKET WIRE)– June 30, 2008 – CDEX Inc. (OTC BB:CEXI) announced today that on June 25, it signed a financing agreement for up to $2.5 million and closed the first $1 million tranche of the financing with Gemini Master Fund, Ltd., an investment fund with offices in New York City and San Diego, CA. The financing is in the form of a two year Convertible Debenture with rights of conversion into CDEX Class A Common Stock at a fixed conversion price.

"As an investor we are attracted to CDEX because their technologies are compelling in two very important markets: improving patient safety in hospitals by validating high-risk medications (the ValiMed™ product line) and detecting trace amounts of illegal substances such as methamphetamine (the ID2, Meth Scanner™ product line)", said Steven Winters, Founder and Portfolio Manager of Gemini Strategies, LLC.  ”We like CDEX’s product market space, management team, expanding client base and technology potential for the future, and are pleased to be an investor in the Company.”

“Over a year ago we began the search for a major investment partner to assist in our road to profitability without jeopardizing the Company’s future or existing shareholders,” said Malcolm Philips, CDEX CEO. “Steve Winters and his Gemini Team have worked with us in fashioning an investment package that accomplishes these goals.  We can now step up the pace of our strategic plans, including expansion of our product portfolio and distribution into global markets for both ValiMed and the Meth Scanner, acceleration of our R&D efforts for market entry of new product lines, and establishing a solid program of investor relations for our existing and new shareholders   On July 8, 2008 at 11:00 a.m. EST, I will hold an open line teleconference to answer questions from investors regarding this financing package (monitor www.cdexinc.com) for details.” 

The ValiMed™ Medication Validation System is used both to train compounding pharmtechs/nurses and to validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication's spectroscopic signature to the expected signature from the ValiMed database to detect significant medication and concentration errors as well as accidental and deliberate contamination, and provides the results in real time.

The CDEX ID2 Meth Scanner™ is a hand held, battery operated device that detects low nanogram range quantities of methamphetamine in a continuous scan mode from standoff distances of around 2-8 inches. The product uses the same proven technology employed in ValiMed™ units around the world to give instantaneous results without disturbing the surfaces under investigation.  The Meth Scanner has wide marketability across law enforcement, military and homeland security markets and growing potential for property inspection, including homes, commercial buildings and automobiles, to assure their freedom from methamphetamine contamination.

About Gemini Strategies, LLC

Gemini is an alternative asset management company that seeks to take advantage of opportunities presented by the fragmentation and dislocation of small-cap markets. Gemini's professionals have been active investors in these niche strategies since 1992. Gemini's focus is on Private Investments in Public Equities (PIPEs) and special opportunities involving small-cap companies. Their experienced deal team has backgrounds in energy, environmental credit markets, healthcare, manufacturing, technology, and telecommunications.

About CDEX Inc.

CDEX, a technology development company currently developing and marketing products using its patented/patent pending chemical detection technologies, is focused on (i) identification of substances of concern (e.g., explosives and illegal drugs, for security markets); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of compounded medication and detection of counterfeit or sub-par products, for the medical and brand protection markets). ValiMed™ and the ID2 Meth Scanner™ are CDEX solutions for the medication safety and security markets. Corporate headquarters and R&D facilities are located in Tucson, Arizona. For more information, visit www.cdexinc.com and www.valimed.com or contact Steve Schmidt (sschmidt@cdex-inc.com) at 520.745.5172.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the Protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

CDEX Focuses on Core Markets and Positions the Company to Respond to Growing Customer Demand in the US and Internationally

Tucson, Arizona – June 3, 2008 – CDEX Inc. (OTCBB: CEXI) follows up on recent announcements of record revenues and international expansion by announcing organization of two new divisions to accommodate its continued growth in both the healthcare and security markets. Effective June 1, 2008, CDEX announces the following actions:

—Mr. Pascal Pouligny will become the VP and General Manager of the newly formed Medication Safety Division.  Mr. Pouligny was formerly CDEX’s VP of International Sales and Marketing.

—Mr. Steven Schmidt, formerly a consultant for CDEX, will join the company as the VP and General Manager of the newly formed Security Division.  Mr. Schmidt has served in a number of senior executive positions in different market areas over the past 30 years, with a primary focus on global sales and marketing.

—Dr. Wade Poteet is appointed Chief Technical Officer, and will work with both divisions to develop next generation technology to meet developing customer needs.

“CDEX is continuing to grow, and in order to keep pace with our expanding market segments and revenue streams I have formed two new divisions that focus on our core markets. The Medication Safety Division includes our current ValiMed product line sold to hospitals as well as future products aimed at the healthcare industry. The Security Division will launch our first product, the Meth Scanner™, and bring other substance detection products to that market,” said Malcolm Philips, CDEX CEO.  “I am extremely pleased to have senior executives heading these two divisions with a strong track record of successful sales and marketing. In addition I have appointed Dr. Wade Poteet as our CTO.  Dr. Poteet has a distinguished career of developing breakthrough technologies and will focus his technology development on our two new divisions.”

The ValiMed™ Medication Validation System is used both to train compounding pharmtechs/nurses and to validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety.  ValiMed compares a medication’s spectroscopic signature to the expected signature from the ValiMed database to detect significant medication and concentration errors as well as accidental and deliberate contamination, and provides the results in real time.

The CDEX ID2 (Meth Scanner™) is a hand held, battery operated device that detects low nanogram range quantities of methamphetamine in a continuous scan mode from standoff distances of around 2-8 inches.  The Meth Scanner uses the same proven technology employed in ValiMed™ units around the world to give instantaneous results without disturbing the surfaces under investigation.

About CDEX, Inc.

CDEX, a technology development company currently developing products using its patented/patent pending chemical detection technologies, is focused on (i) identification of substances of concern (e.g., explosives and illegal drugs, for security markets); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of compounded medication and detection of counterfeit or sub-par products, for the medical and brand protection markets). ValiMed™ and the Meth Scanner™ are CDEX solutions for the healthcare and security markets.  Corporate headquarters and R&D facilities are located in Tucson, Arizona.  For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) at 520.745.5172 X210.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the Protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Sec. There is no obligation to publicly update any forward-looking

ValiMed™ Medication Validation System is currently installed at four major hospitals in Europe and the Middle East.

Tucson, Arizona – May14, 2008 – CDEX Inc. (OTCBB: CEXI) follows up on recent announcements regarding international expansion by announcing today the installation of ValiMed at the Vall d’Hebron University Hospital in Barcelona, Spain, and at a major hospital located in Al Ain, Abu Dhabi, United Arab Emirates, for technical and clinical testing. Including the Hammersmith and Charing Cross hospitals in London, ValiMed is now installed for technical and clinical testing in four flagship hospitals across Europe and in the Middle East.

The ValiMed Medication Validation System is used both to train compounding pharmtechs/nurses and to validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the ValiMed database to detect significant medication and concentration errors as well as accidental and deliberate contamination, and provides the results in real time.

“The Vall d’Hebron University Hospital, characteristic of each of our four international cooperative partners, is one of world’s most forward thinking medical facilities, is driven by excellence in patient care and has a long and impressive record in improving medication safety throughout its region,” said Malcolm Philips, CDEX President and CEO. “We are honored that each of these flagship healthcare institutions has elected to partner with CDEX in testing the ValiMed system and establishing new standards and processes for patient medication safety.”

About CDEX Inc.

CDEX, a technology development company currently developing products using its patented/patent pending chemical detection technologies, is focused on (i) identification of substances of concern (e.g., explosives and illegal drugs, for security markets); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of compounded medication and detection of counterfeit or sub-par products, for the medical and brand protection markets). ValiMed™ and the Meth Scanner™ are CDEX solutions for the healthcare and security markets.  Corporate headquarters and R&D facilities are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Pascal Pouligny (ppouligny@cdex-inc.com) at 520.745.5172.

About Valld’Hebron University Hospital

Vall d’Hebron University Hospital, the leading hospital complex in Catalonia and one of the largest in Spain, is comprised of four large centers - the General Area, the Maternity and Children's Area, the Trauma and Rehabilitation Area and the Outpatient Surgery Unit. The Vall d’Hebron University Hospital, with a total of more than 1400 beds strives for optimum health care delivery. More information about Vall d’Hebron Hospital can be found at http://www.vhebron.es/vhang.htm.

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

The ValiMed™ Signature Library of 167 signatures now has seven signatures of heparin such as produced by Baxter Healthcare Corporation (NYSE: BAX) and Hospira Inc (NYSE: HSP), including typical neonatal and pediatric doses

Tucson, Arizona – May 8, 2008 - CDEX Inc. (OTCBB: CEXI) announces that it now has seven heparin Signatures in its ValiMed™ Signature Library encompassing a range of concentrations and diluents, including typical neonatal and pediatric doses.  (A signature is an electronic fingerprint of a medication at a given concentration in a prescribed diluent.)  ValiMed is used both to train compounding pharmtechs/nurses and to validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety.  ValiMed compares a medication’s spectroscopic signature to the expected signature from the ValiMed database to detect significant medication and concentration errors as well as accidental and deliberate contamination, and provides the results in real time. (For a complete list of the ValiMed Signatures, see www.cdex-inc.com.) 

“Based on the recent medication errors and contamination events associated with heparin, our clients requested that we develop an expanded grouping of heparin Signatures for ValiMed,” said Stuart Poteet, Manager of Marketing and Client Support. “The heparin Signatures developed are weighted heavily toward the neonatal and pediatric doses and will provide an increased measure of safety for the patients in hospitals using ValiMed. When the CDEX Team develops a ValiMed signature, we test over 400 separate samples of the medication mixture.  Then each potential signature is scrubbed though a number of practical and medical gates and sent through a concentration/dilution study before being placed in the CDEX Library for use by our clients.  ValiMed can identify not only significant errors in medication and concentration, but also counterfeit or terrorist contaminated medications before they compromise the pharmaceutical supply chain.”   

About CDEX Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas:  (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market.  Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona.  For more information, visit www.cdex-inc.com or contact Malcolm Philips (mphilips@cdex-inc.com) at 520.745.5172 X 210 or 207.

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Tucson, Arizona – May 5, 2008 - CDEX Inc. (OTCBB: CEXI) announces the appointment of General Robert H. Foglesong, U.S. Air Force (Retired), to its Board of Directors, effective May 1, 2008.  General Foglesong (ret) is currently the President and Executive Director of the Appalachian Leadership and Education Foundation, a non-profit foundation operating to identify the next generation of leaders in Appalachia and to support their journey toward academic, leadership, and character excellence.  Previously, he served as the 18th President of Mississippi State University and has had a long and distinguished career in the U.S. Air Force serving in various positions including Commander, U.S. Air Forces in Europe and Vice Chief of Staff of the Air Force. General Foglesong (ret) is a graduate of West Virginia University (BS, MS and PhD – Chemical Engineering) and serves on the Board of Directors of Massey Energy (NYSE: MEE) and Michael Baker Corporation (AMEX: BKR).  (For a more complete bio, click here.)  

“I'm honored and delighted to be part of the CDEX Team,” said General Foglesong (ret).  “The character of the organization and the work ethic of the CDEX employees speak volumes about the upward potential and the quality of the products CDEX provides -- nationally and internationally.  I'm excited to be in this formation!"  

“Doc Foglesong is a man of integrity and moral conviction, with a world view shared by the CDEX Team”, said Malcolm Philips, CDEX CEO and Chairman of the Board.  “Leading organizations and bringing assets together to solve problems in national and international settings has been Doc Foglesong’s life work.  That is also the CDEX vision as we assist in addressing major world problems such as medication errors, illegal drug use, explosive detection and distribution channels contaminated by counterfeit products.  Doc Foglesong will be a major addition to the CDEX Team as we continue to move products into the mainstream national and international markets that assist with solving these problem.  We are both pleased and honored that he has joined us in this work.”

About CDEX Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas:  (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market.  Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona.  For more information, visit www.cdex-inc.com or contact Malcolm Philips (mphilips@cdex-inc.com) at 520.745.5172 X 210 or 207.

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

CDEX  CEO Malcolm Philips will appear on The 3 Minute Press Show on www.WallSt.net on Monday,  April 14, 2008 (http://tv.wallst.net/3-min-press/3-min-press.php)

Tucson, Arizona – April 14, 2008 – CDEX Inc. (OTCBB: CEXI) announces record sales/leases of ValiMed™ units in its 2nd fiscal quarter ending April 30, 2008.  “With the strong market demand and increasing number of hospitals in our customer pipeline both domestically and internationally, we have significantly increased the size of our current production run for ValiMed units,” said Tim Shriver, CDEX COO.  “We have now ordered all of the major components for 115 Units, allocated for both the national and international markets.”

The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety.  ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.

“At the annual CDEX Shareholders Meeting , I emphasized that the 2008 goals for ValiMed relate primarily to increased revenue, strengthening our internal marketing arm, establishing strong international distribution channels in the three primary regions of focus and expanding the ValiMed product line to offer attractively priced products to all levels of the health care market”, said Malcolm Philips, CDEX CEO.  “We are tracking well to these goals. We expect to close the second quarter with ten new sales/leases of ValiMed units .  CDEX revenues increased approximately 80% from 2006 to 2007, and we believe will substantially increase in 2008 based on our ValiMed product line alone, not including sales from our Meth Scanner™ which we expect to begin next quarter. We are pleased with this increasing number of ValiMed units in the field, which translates into an increasing recurring revenue stream, such as from sale of our patent pending cuvettes used with each ValiMed unit.”  

About CDEX Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas:  (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market.  Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona.  For more information, visit www.cdex-inc.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Cynthia Sampson (csampson@cdex-inc.com) at 520.745.5172 X 210 or 207.

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

CDEX Inc and Grifols International SA to enter into distribution agreement for the ValiMed™ Medication Validation System in Southern Europe.

Tucson, Arizona and Barcelona, Spain – April 9, 2008 – CDEX Inc. (OTCBB: CEXI) follows up on recent announcements regarding international expansion by announcing today a business partnership agreement with GRIFOLS International SA to distribute ValiMed™ in Spain, Portugal and Italy. The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety.  ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.

“At Grifols we strive to provide hospitals with innovative products and services that improve the quality, efficiency and effectiveness of patient care”, said Xavier Guix, Marketing Director at Grifols International SA. “ValiMed integrates well with that vision by bringing new and unique standards to enhance patient medication safety. We are very excited about this new relationship with CDEX.”

“We are very honored that a Company like Grifols, driven by high quality and ethical standards is taking our products on board and we look forward to developing a strong and long lasting relationship that will directly benefit our customers in Southern Europe” said Malcolm Philips, CDEX President and CEO. “Patient Medication Safety is a global concern and a top priority in all hospitals. This announcement marks another concrete step in our goal of making ValiMed a safety standard worldwide.”

About CDEX Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas:  (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market.  For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Pascal Pouligny (ppoulignyt@cdex-inc.com) at 520.745.5172 X 210.

About GRIFOLS International SA.

Grifols is a holding company specialized in the pharmaceutical hospital sector and present in more than 90 countries. Grifols has been present in healthcare since 1940, creating innovative products and services based on the values of ethics and responsibility. Grifols' activities focus on fulfilling the needs of healthcare professionals working in therapeutics, pharmacy, diagnostics and blood banking. For more than 60 years, Grifols has developed, manufactured and marketed products designed to improve human health. The company manufactures products of proven efficacy, quality and safety. More information about Grifols can be found at http://www.grifols.com. Since 2006 the company is present on the stock exchange as GRF.MC and was included on the prestigious IBEx-35 group of companies in Spain starting on January 2008..

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

CDEX Inc and Virtus Trading LLC to enter into distribution agreement for the ValiMed™ Medication Validation System in the Middle East.

Tucson, Arizona and Abu Dhabi, U.A.E – April 7, 2008 – CDEX Inc. (OTCBB: CEXI) follows up on recent announcements regarding international expansion by announcing today a business partnership agreement with Virtus Trading LLC (a subsidiary of Virtus Al-Essa Company W.L.L. in Kuwait) to distribute ValiMed™ in Kuwait, The United-Arab-Emirates, Bahrain and Qatar. The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety.  ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.

“Pharmacy automation and patient medication safety are a strategic focus for our Company. We anticipate a great interest for ValiMed in the Middle East given current momentum on raising patient care standards across the Region” said Anil Pinto, Executive Director at Virtus Trading LLC. “We at Virtus & Virtus Al-Essa look forward to a very long and successful association with CDEX.”

“We are honored to partner with Virtus in bringing the ValiMed technology to Middle East hospitals.  They share with CDEX and its growing number of ValiMed distributors and clients a passion for patient safety and quality customer service,” said Malcolm Philips, CDEX President and CEO.  “Some of the finest hospitals and clinics in the US are currently participating in implementation of the healthcare system in the Middle East and this should facilitate the introduction of ValiMed into the region.”

About CDEX Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas:  (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market.  For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Pascal Pouligny (ppoulignyt@cdex-inc.com) at 520.745.5172 X 210.

About Virtus

Drawing on 30+ years of experience in founding and building business in Kuwait, & our commitment to the healthcare industry in the Gulf, Virtus Trading L.L.C was established with the objective of  “Making the difference….” on a regional basis:

— To the medical fraternity by introducing innovative products & technologies to improve treatment outcomes and patient medication safety.

— To patients by offering clinicians newer methods & tools for treatment modalities

— To employees by providing a platform for expansion and opportunity for growth

— To customers through top notch clinical and product support

Our range of activities involves supplying products, installation, providing application support, clinical support and maintenance for medical & analytical needs. We can deliver complete solutions in facility engineering, providing mechanical piping, furniture, furnishing and equipment.
Our ability to undertake this comprehensive range of activities in the region comes from more than 30 years of corporate experience in managing the Al-Essa Group of Companies, a premier company engaged in delivering total solution in the Healthcare & Scientific Sector in Kuwait.
We are proud of our unparalleled reputation for providing quality solution, the result of a coporate ethos that has won recognition from our valued customers. More information about Al-Essa can be found at http://www.alessakuwait.com.

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

CDEX Meth Scanner™ identifies methamphetamine in four different jurisdictions and detects methamphetamine below the proposed California health-based remediation standard

Tucson, Arizona – March 28, 2008 - CDEX Inc. (OTCBB: CEXI) announces that its ID2 (Meth Scanner™) correctly identified 32 different samples of methamphetamine in clear containers in four different law enforcement jurisdictions with no errors, including Rose, Strawberry, Mexican, Peanut Butter and Crystal Meth types.  In a separate sensitivity test, the CDEX Meth Scanner identified methamphetamine at 1.0 micrograms/100 cm2 (10 nanograms/cm2), below the proposed California health-based methamphetamine remediation standard of 1.5 micrograms/100cm2 (15 nanograms/cm2).

“We have received great cooperation from police departments across the nation offering to let us test the Meth Scanner against the methamphetamine samples in their possession,” said Tim Shriver Jr. “We are already in our production cycle for the first 200 Meth Scanners and expect delivery of the first Scanners to a waiting client base during the 2nd Quarter 2008. There has been interest from all over the world in many use areas ranging from police and school districts to property inspectors and hospitals.”

The CDEX ID2 (‘Meth Scanner”) is a hand held, battery operated device that detects low nanogram range quantities of methamphetamine in a continuous scan mode from standoff distances of around 2-8 inches.  The Meth Scanner gives instantaneous results without disturbing the surfaces under investigation.  Meth Scanner technology is used in the CDEX ValiMed™ Medication Validation System currently deployed in major hospitals across the United States. (See www.cdex-inc.com or www.valimed.com )

“While the direct impacts of methamphetamine use are devastating, the broader impact on the unsuspecting public is the real ticking time bomb,” said Malcolm Philips, CDEX CEO.  “We do not fully understand the long term health impacts of passive exposure to methamphetamine, such as from a home/apartment/hotel or used automobile where meth was used or made, or working in those locations.  We do know that the immediate health impacts can be life threatening and long term impacts may result in cancer, as we have seen in numerous first hand reports and studies.  In addition to assisting police forces, we believe that the Meth Scanner will provide a quick and low cost tool to identify hazardous locations before entry/purchase which will minimize overall risk to the public.”

About CDEX, Inc.

CDEX, a technology company currently developing products using its patented/patent pending chemical detection technologies, is focused on (i) identification of substances of concern (e.g., explosives and illegal drugs, for security markets); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of compounded medication and detection of counterfeit or sub-par products, for the medical and brand protection markets). ValiMed™ and the Meth Scanner™ are CDEX solutions for the healthcare and security markets.  Corporate headquarters and R&D facilities are located in Tucson, Arizona.  For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Tim Shriver Jr. (tshriverjr@cdex-inc.com) 520.745.5172 X 201.

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Timothy Shriver appointed COO and Carlos Alvarez appointed VP of Technical Operations.

TUCSON, AZ. – February 19, 2008 - CDEX Inc. (OTCBB: CEXI) announces that Timothy Shriver and Carlos Alvarez have been appointed Chief Operating Officer and Vice President of Technical Operations, respectively. Both Mr. Shriver and Mr. Alvarez are long term CDEX employees who have played key roles in developing CDEX’s patented technologies into world class products that are saving lives today. (Mr. Shriver’s and Mr. Alvarez’s bios are on the CDEX web site at www.cdex-inc.com).

“As our COO, Mr. Shriver will ensure that our technology and product development programs are coordinated with the growing market demand for our products, both in the US and internationally”, said Malcolm Philips, CDEX CEO. “Mr. Shriver will spearhead implementation of our technical game plan for International expansion efforts for ValiMed™ and the Meth Scanner™. Those efforts started on February 11 with installation of ValiMed units in the Hammersmith and Charing Cross Hospitals in London. As VP of Technical Operations, Mr. Alvarez takes over the day-to-day technical activities of the CDEX Team, including the upcoming production runs for both the Meth Scanner and ValiMed.”

CDEX is a technology company that currently has two product lines in different commercial markets. The CDEX ID2 (‘Meth Scanner™”) is a hand held, battery operated scanner that detects low nanogram range quantities of methamphetamine from standoff distances of 2-8 inches without disturbing the surfaces under investigation. Meth Scanner technology is used in the CDEX ValiMed™ Medication Validation System currently deployed in major hospitals across the United States. (See www.cdex-inc.com or www.valimed.com )

About CDEX, Inc.

About CDEX, Inc. CDEX Inc. (OTCBB: CEXI), the manufacturer of the ValiMed™ System, is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (I) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (II) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact CDEX, Inc. at 888.701.CDEX (2339) or cdexmanagement@cdex-inc.com.

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

TUCSON, AZ.,–February 14, 2008- CDEX Inc. (OTCBB:CEXI) announces filing of its 10KSB for fiscal year 2007, reporting, among other things, record sales to U.S. hospitals, expansion of the ValiMed™ Signature Library to over 150 signatures, international expansion of the ValiMed Product Line, development of the Meth Scanner™ as a second product line, the highest annual revenue in the Company’s history and gross margins continued in excess of 50%.

ValiMed uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. Using the patented/patent pending technologies proven by ValiMed, the hand-held CDEX ID2 (“Meth Scanner”) detects low nanogram range quantities of methamphetamine on surfaces, in a continuous scan mode from standoff distances of 2-8 inches.

“2007 saw significant expansion of ValiMed into the national and international medical markets, and final preparation of the Meth Scanner for sales into the national security and property inspection markets – two product lines addressing major problems in independent markets,” said Malcolm Philips, President and CEO. “We have met virtually all of the goals that we set for 2007 and look forward to 2008 as another year of significantly increasing revenues.”

The Company has scheduled a 45 minute conference call for interested persons for Tuesday, February 19 at 10:00 AM EST to discuss the SEC filing. The call will be limited to the first 50 individuals to call in. A recording of the call is posted on the Company’s web site here.

About CDEX, Inc.

CDEX Inc. (OTCBB: CEXI), the manufacturer of the ValiMed™ System, is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (I) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (II) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact CDEX, Inc. at 888.701.CDEX (2339) or cdexmanagement@cdex-inc.com.

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

UK's first Academic Health Science Centre incorporating London’s St Mary's and Hammersmith Hospitals, in partnership with Imperial College London to test ValiMed™ in clinical pharmacy settings and engage in new product development.

Tucson, Arizona and London, England – January 23, 2008 – CDEX Inc. (OTCBB: CEXI) follows up on recent announcements regarding international expansion by announcing today a partnership cooperation with the Imperial College Healthcare NHS Trust in London to test ValiMed in the Hammersmith and Charing Cross hospitals and to work together in developing new medication signatures including chemotherapy and cytostatic drugs. The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.

On January 7, 2008, CDEX announced publication of an 18 month independent study of the ValiMed™ Medication Validation System at the C.S. Mott Children's Hospital in the University of Michigan Health System in the American Journal of Health-System Pharmacists. “During the 18 months since [ValiMed] was implemented, five potentially serious medication errors have been detected and avoided,” the report stated. “[ValiMed] consistently validated the correct solution, while dependably detecting as invalid the wrong drug or concentrations that departed substantially from the targeted standard.” The press release from the University of Michigan can be accessed at http://www.ns.umich.edu/htdocs/releases/story.php?id=6255.

“We are delighted to have this opportunity to work in partnership with CDEX. By working in collaboration we will ensure product development is completely aligned with patient need to the mutual benefit of all,” said Professor Ann Jacklin, Chief Pharmacist at Hammersmith & Charing Cross hospitals, Imperial College Healthcare NHS Trust, and Visiting Professor at The School of Pharmacy University of London. In 2000 Ms. Jacklin initiated the formation of the Centre for Medicines Safety and Service Quality, a joint research centre between Hammersmith Hospital and the School of Pharmacy, and has been joint Chair of the centre since this time.

“We are honored that Professor Jacklin and her staff have elected to partner with CDEX in testing the ValiMed technology and developing new applications and signatures that will dramatically increase patient medications safety where it is most needed” said Malcolm Philips, CDEX President and CEO. “This marks another step in developing a global coalition of world class hospitals working together to address major medication delivery issues.”

About CDEX, Inc.

CDEX Inc. (OTCBB: CEXI), the manufacturer of the ValiMed™ System, is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (I) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (II) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact CDEX, Inc. at 888.701.CDEX (2339) or cdexmanagement@cdex-inc.com.

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

August DeLuca appointed CFO and VP of Finance of CDEX Inc

Tucson, Arizona – January 22, 2008 - CDEX Inc. (OTCBB: CEXI) announces that August F. DeLuca has been appointed Chief Financial Officer and Vice President of Finance. Mr. DeLuca has been CDEX’s acting CFO for the past nine months. In his new role, Mr. DeLuca will supervise all accounting and financial activities, treasury, financial modeling and risk management. Mr. DeLuca has a distinguished career of over 30 years of service in senior level financial positions. He has served as CFO of a number of companies, both public and private.

“CDEX is a cutting edge, technology/product development company that fits well with my technical, financial and management background,” said Mr. Deluca. “The products that we are bringing to the marketplace are addressing major problems which makes the job both interesting and internally rewarding. I look forward to helping CDEX achieve its potential in the national and international arenas.”

“Augie has been an invaluable part of the CDEX Team over the past nine months, as he has guided our financial activities,” said Malcolm Philips, CDEX CEO. “We are pleased that he has decided to join the Team on a more formal basis and become our CFO and VP of Finance, as well. With his financial leadership and the recent addition of financial expertise on our Board, we will be able to chart a more effective financial course as we expand and diversify our revenue base into other commercial markets.”

CDEX is a technology company that currently has two product lines in different commercial markets. The CDEX ID2 (“Meth Scanner™”) is a hand held, battery operated scanner that detects low nanogram range quantities of methamphetamine from standoff distances of 2-8 inches without disturbing the surfaces under investigation. Meth Scanner technology is used in the CDEX ValiMed™ Medication Validation System currently deployed in major hospitals across the United States. (See www.cdex-inc.com or www.valimed.com)

About CDEX, Inc.

CDEX Inc. (OTCBB: CEXI), the manufacturer of the ValiMed™ System, is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (I) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (II) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact CDEX, Inc. at 888.701.CDEX (2339) or cdexmanagement@cdex-inc.com.

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Mr. David Smuts joins CDEX Inc. to spearhead marketing and sales of ValiMed™ in the UK

Tucson, Arizona; Paris, France and London, England – January 17, 2008 – CDEX Inc. (OTCBB: CEXI) follows up on recent announcements regarding international business development by announcing today that Mr. David Smuts has joined CDEX to drive the marketing and sales of ValiMed in the United Kingdom and Ireland. The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.

Mr. Smuts is a seasoned and knowledgeable business manager experienced in working with senior level executives in the government and the public/private sectors of the healthcare industry. He has a proven track record of initiating and developing new technology solutions for the international healthcare market. Most recently, Mr. Smuts was the Business Manager for Cardinal Health Inc.’s Pyxis pharmacy automation solution for the UK and Ireland, where he developed reference test sites, drove quick adoption of the new-to market technologies and secured record contracts with the National Health Service. Currently Mr. Smuts chairs the Health Study Group of the UK Labour Finance and Industry Group (LFIG), which provides policy advice to government ministers including those from the department of health.

“Prevention of medication errors and improving patient safety are top priorities within all hospitals in the UK and in particular at all levels in the National Health Service,” said Mr. Smuts. “ValiMed provides a unique solution to help pharmacists and care givers work towards this goal.”

“We are very pleased to have someone of David’s caliber and experience to lead our sales and marketing efforts in the UK and in Ireland” said Pascal Pouligny, CDEX Vice President of International Sales & Marketing. “This is a very important step in our international development plan and we are very committed to providing our UK customers with excellent sales and service support from day one. We also hope to announce further appointments in the near future”

About CDEX, Inc.

CDEX Inc. (OTCBB: CEXI), the manufacturer of the ValiMed™ System, is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (I) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (II) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact CDEX, Inc. at 888.701.CDEX (2339) or cdexmanagement@cdex-inc.com.

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

New York—On January 15, Malcolm Philips, Jr., President and CEO of CDEX Inc. (OTCBB: CEXI) (www.cdex-inc.com) updated the investment community in an all-new interview with www.wallst.net. Topics covered in the interview include an overview of the company and its growth strategy, recent press releases, market opportunity, and upcoming milestones for investors to watch for.

To hear the interview in its entirety, visit http://www.wallst.net, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange on the top of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window.

About CDEX, Inc.

CDEX Inc. (OTCBB: CEXI), the manufacturer of the ValiMed™ System, is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (I) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (II) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact CDEX, Inc. at 888.701.CDEX (2339) or cdexmanagement@cdex-inc.com.

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

New York—Malcolm Philips, Jr., Chief Executive Officer of CDEX, Inc. (OTCBB: CEXI) (www.cdex-inc.com) will be featured in an exclusive interview with www.wallst.net scheduled for January 15 at 11 a.m. EST. The interview will be posted on www.wallst.net by 8 p.m. EST on January 15.

The interview will cover topics including CDEX’s market potential, growth initiatives, competitive edge, recent news, and milestones for which investors should watch.

To hear the interview in its entirety, visit http://www.wallst.net and click on "Interviews." The interview can be accessed by locating the company's ticker symbol under the appropriate exchange at the top of the "Interviews" section or by entering the company's ticker symbol in the Search Archive window.

About CDEX, Inc.

CDEX Inc. (OTCBB: CEXI), the manufacturer of the ValiMed™ System, is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (I) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (II) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact CDEX, Inc. at 888.701.CDEX (2339) or cdexmanagement@cdex-inc.com.

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Exposure to “second-hand methamphetamine” left in houses, apartments and hotel rooms can result in devastating health and economic consequences. The CDEX Meth Scanner™ detects meth down to the low nanogram range

Tucson, Arizona – January 9, 2008 - CDEX Inc. (OTCBB: CEXI) will demonstrate the Meth Scanner™ at the ASHI Inspection World Conference in New Orleans, Louisiana January 16-19, 2008. Inspection World is the largest annual professional gathering for Home Inspectors in the United States. The health impact of moving into a meth contaminated house, apartment or hotel room can be tragic, particularly for children. Moreover, the unsuspecting new homeowner or mortgage lender is often burdened with a massive cleanup cost. Now in a 5-10 minute, low cost add-on to a routine home inspection, a Property Inspector using the Meth Scanner can give the prospective homeowner an instantaneous answer – “Meth Clean” or “Stay Away”!

The CDEX ID2 (‘Meth Scanner”) is a hand held, battery operated device that detects low nanogram range quantities of methamphetamine in a continuous scan mode from standoff distances of 2-8 inches. The Meth Scanner gives instantaneous results requiring no operator interpretation without disturbing the surfaces under investigation. Meth Scanner technology is used in the CDEX ValiMed™ Medication Validation System currently deployed in major hospitals across the United States. (See www.cdex-inc.com or www.valimed.com )

About CDEX, Inc.

CDEX Inc. (OTCBB: CEXI), the manufacturer of the ValiMed™ System, is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (I) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (II) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact CDEX, Inc. at 888.701.CDEX (2339) or cdexmanagement@cdex-inc.com.

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

ValiMed™ detected five potentially serious medication errors while consistently validating the correct medication solutions during an 18 month study at a major University Hospital.

Tucson, Arizona – January 7, 2008 – CDEX Inc. (OTCBB: CEXI) announces publication of an 18 month independent study of the ValiMed™ Medication Validation System at the C.S. Mott Children's Hospital in the University of Michigan Health System in the American Journal of Health-System Pharmacists. “During the 18 months since [ValiMed] was implemented, five potentially serious medication errors have been detected and avoided,” the report stated. “[ValiMed] consistently validated the correct solution, while dependably detecting as invalid the wrong drug or concentrations that departed substantially from the targeted standard.” (Am J Health-Syst Pharm--Vol 65, pp 49-54, Jan 1, 2008, "Enhanced Photoemission Spectroscopy for Verification of High-Risk IV Medications”).

"Errors in compounding these types of medications are rare. However, when they occur they can have a significant negative impact on patients and staff," said one of the authors, Jim Stevenson, Associate Dean of Clinical Sciences at the University of Michigan College of Pharmacy and Director of Pharmacy Services at the University’s Health System. "Our goal is to have zero tolerance for errors. We know from having ValiMed™ in place we've deterred five potentially serious errors that might have happened. I really believe having technology like this needs to be the standard around the country." (Stevenson's statements are drawn from a University of Michigan press release and are quoted with permission (see http://www.ns.umich.edu/htdocs/releases/story.php?id=6255.)

“This peer reviewed Study was a comprehensive analysis of our patented technologies and first generation ValiMed units,” said Malcolm Philips, CDEX CEO. “Jim Stevenson and his Staff at the University of Michigan Health System are among the best and most forward thinking heath care organizations in the nation, with a zero tolerance policy for medication errors. They have stepped forward to tackle a significant problem facing the entire medical community and we look forward to working with them and other top rated national and international hospitals in our collective efforts to provide the best standard of care for patients.”

ValiMed™ uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to its expected CDEX Library signature and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.

About CDEX, Inc.

CDEX Inc. (OTCBB: CEXI), the manufacturer of the ValiMed™ System, is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (I) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (II) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact CDEX, Inc. at 888.701.CDEX (2339) or cdexmanagement@cdex-inc.com.

Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.